]>
IRCT201011075117N1 IRCT 2011-01-28 Ahvaz Jundishapur University of Medical Sciences Comparation the efficacy of zonisamide and topiramate in migraine prophylaxis Zonisamide versus Topiramate in migraine prophylaxis: a double-blind randomized clinical trial 2009-07-08 anticipated 80 Complete https://irct.ir/trial/5449 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A Migraine. Intervention 1: Zonisamide capsule, 50-200 mg once day for 3 months in the intervention group. Intervention 2: topiramate tablet 25-100 mg/day BID or twice in day for 3 month in control group.
public Dr Vahid Abbasi
Golestan hospital, Ahvaz
Ahvaz Iran (Islamic Republic of) +98 61 1374 3003 V.abbasineuro@yahoo.comVahid.Abbasi@ajums.ac.ir Ahvaz Jundishapur University of Medical Sciences scientific Dr Seyed Ehsan Mohammadiani neghad
Golestan hospital, Ahvaz
Ahvaz Iran (Islamic Republic of) 00986113743003 ehsan_neuro@yahoo.com Ahvaz Jundishapur University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: history of classic or common migraine that met International Headache Society (HIS) criteria, which is at least one year of past disease, number of migraine attacks at least four times per month and less than 15 times per month, or even when they occur less than four times per month but migraine attacks are very prolonged and debilitating that require preventive treatment, postmenopausal women who pass at least one year of their menopause, negative pregnancy test, using appropriate contraceptive during the study, no consumption of topiramate or Zonisamide Exclusion criteria: suffering from other than migraine headaches such as tension headaches, periodic headaches and sinusitis, presence of any cause of pain that must be used medications regularly, history of hypersensitivity to topiramate or zonisamide 12 years 65 years Both G43 Migraine Treatment - Drugs Treatment - Drugs Zonisamide capsule, 50-200 mg once day for 3 months in the intervention group topiramate tablet 25-100 mg/day BID or twice in day for 3 month in control group Headache frequency. Timepoint: before trial , 1 month and 3 month after trial. Method of measurement: Questionnaire. Use of acute medication. Timepoint: before trial , 1 month and 3 month after trial. Method of measurement: Questionnaire. Headache severity. Timepoint: before trial , 1 month and 3 month after trial. Method of measurement: Questionnaire. MIDAS score. Timepoint: before trial and 3 month after trial. Method of measurement: Questionnaire. Drugs complications. Timepoint: before trial, 1 month and 3 months after trial. Method of measurement: Questionnaire. Ahvaz Jundishapur University of Medical Sciences Approved 2009-06-14 Ahvaz Jundishapur University of Medical Sciences Golestan street, ahvaz Ahvaz Iran (Islamic Republic of)